Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | H1047X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | PIK3CA H1047X indicates any Pik3ca missense mutation that results in the replacement of the histidine (H) at amino acid 1047 by a different amino acid. PIK3CA H1047X mutations are hotspot mutations that may result in increased Pik3ca kinase activity and cell transformation in culture (PMID: 15930273). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA exon21 PIK3CA H1047X |
Transcript | NM_006218.4 |
gDNA | chr3:g.179234296_179234298 |
cDNA | c.3139_3141 |
Protein | p.H1047 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713658.5 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179234296_179234298 | c.3139_3141 | p.H1047 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA H1047X | endometrial adenocarcinoma | predicted - sensitive | Temsirolimus | Case Reports/Case Series | Actionable | In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929). | 21216929 |
PIK3CA H1047X | colorectal cancer | predicted - resistant | Bevacizumab + Temsirolimus | Case Reports/Case Series | Actionable | In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). | 21216929 |
PIK3CA H1047X | small intestine adenocarcinoma | predicted - resistant | Bortezomib + Temsirolimus + Topotecan | Case Reports/Case Series | Actionable | In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929). | 21216929 |
PIK3CA H1047X | lung non-small cell carcinoma | sensitive | Taselisib | Phase I | Actionable | In a Phase I trial, a non-small cell lung carcinoma patient harboring a mutation at PIK3CA H1047 demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003). | 28331003 |
PIK3CA H1047X | endometrial adenocarcinoma | no benefit | Copanlisib | Case Reports/Case Series | Actionable | In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in progressive disease in a patient with endometrioid adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 31934607). | 31934607 |
PIK3CA H1047X | endometrial mixed adenocarcinoma | no benefit | Copanlisib | Case Reports/Case Series | Actionable | In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in progressive disease in a patient with endometrial mixed adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 31934607). | 31934607 |